鹤草酚对肺腺癌放射增敏的临床前瞻性研究

A clinical prospective study of radiosensitization on lung adenocarcinoma by agrimophol

目的 通过对肺腺癌放射增敏的临床研究 ,探讨鹤草酚放射增敏的治疗效果。方法采用双盲法将 12 2例肺腺癌患者分为两组 ,放射增敏组病人在放疗过程中 ,每日两次口服中药提取物鹤草酚 ,对照组病人口服安慰剂。在基础因素和治疗条件大致相等的情况下 ,观察两组患者的不同治疗结果。结果 放射治疗结束时 ,增敏组病人的肿瘤完全缓解 (CR)率与对照组相比增加4 1 4 %。放疗结束后 5年内 ,增敏组患者 1,3,5年生存率与对照组相比 ,分别提高 2 3 2 %、17 2 %和12 7%。两组患者放射性肺炎的发生率和肿瘤远处转移率相比较无统计学意义 ,增敏组病人胸水发生率和病灶复发率显著低于对照组。结论 鹤草酚在对肺腺癌细胞产生放射增敏作用的同时 ,不仅对肺腺癌患者放射性肺炎的发生和肿瘤远处转移无明显影响 ,而且还能显著减少其治疗后胸水的发生和病灶的复发。

Objective To explore the curative effect of radiosensitization by agrimophol through a clinical prospective study on lung adenocarcinoma treated by radiotherapy. Methods A total of 122 patients with lung adenocarinoma were divided into two groups randomly by double blind method :the radiosensitization group (given agrimophol orally, BID )and the control group(given placebo). Curative effects were observed in these two groups treated using the same foundational factors and treatment conditions in the course of radiotherapy. Results The CR rate of tumor increased by 41.4% in the radiosensitization group compared with the control group at the end of radiotherapy. The 1-, 3-,and 5-year survival rate of the radiosensitization group increased by 23.2%, 17.2% and 12.7% ,respectively, compared with that of the control group after radiotherapy. There were no statistic differences in radiopneumonitis incidence and tumor distant metastasis rate between these two groups. The incidence of pleural fluid and the relapse rate of tumor in the radiosensitization group were significantly lower than that of the control group. Conclusions Agrimophol can significantly exert radiosensitization effect on lung adenocarcinoma cells, but does not affect development of radiopneumonitis and tumor distant metastasis. At the same time,agrimophol can significantly reduce the incidence of pleural fliud and tumor relapse after radiotherapy. ;